Feature | May 18, 2015

Proton Therapy World Market Expected to Reach $1 Billion in 2019

Number of treatment rooms available to patients projected to more than double in five years

MEDraysintell, proton therapy, world market, third edition, $1 billion, 2019

May 18, 2015 — For the first time the proton therapy world market is anticipated to reach $1 billion in 2019, according to the third edition of the World Proton Therapy report from MEDraysintell. According to the report, almost 330 proton therapy treatment rooms will be available to patients, a jump from the 141 proton therapy treatment rooms operational in 2014 worldwide. However, by 2019 only 1 percent of the population that requires some sort of radiotherapy will be able to get a proton therapy treatment.

The global particle therapy devices market (mainly proton therapy devices) reached the $100 million level for the first time in 2000 and saw an average annual growth rate from 2000 to 2014 of almost 15 percent. Growth has accelerated during the last four years, showing an average annual growth rate of 22 percent from 2010 to 2014. The proton therapy world market is projected to reach between $3.5 to 6.6 billion by 2030, with 1,200 to 1,800 particle therapy treatment rooms open to patients worldwide.

During 2014, about 14,500 patients were treated worldwide with particle therapy, with a total estimated cost of $400 million. By 2030, it is expected that 300,000 to more than 600,000 patients will be treated with particle therapy.

Today there are 15 manufacturers or developers of proton and carbon therapy equipment, and by 2019 almost 70 percent of the PT market will be shared by five of these companies, including IBA and Varian.

Cost hurdles have certainly been an important factor in the slow adoption of proton therapy facilities in the recent past. Going forward, with the entry of Varian in 2007, the emergence of new vendors, the recent introduction of lower-cost/compact systems (a third of the new PT centers that opened their doors during the last two years were single-treatment-room centers), and, more importantly, a growing number of clinical evidence regarding its efficacy, particle therapy will progressively be used to treat a broader number of indications. Therefore, there is now a clear positive stance on the future of the proton therapy market, and it is becoming a real part of the global radiotherapy world.

The race now continues to develop even smaller and cheaper proton therapy systems. Almost all proton therapy vendors already have, or are developing, a compact PT system. In addition to proton therapy, there is also an increase interest toward carbon therapy, with the emergence of several projects in a few regions of the world and the most recent partnership between IBA and Toshiba to promote Toshiba’s carbon therapy solutions outside of Japan.

The third edition of the World Proton Therapy report is a 250-page document featuring a comprehensive review of the market dynamics on a world basis. It analyzes both past and future trends to the year 2030, and contains a detailed profile of 20 promoters, manufacturers or developers of proton and carbon therapy equipment.

For more information: www.medraysintell.com

Related Content

Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
FDA Clears GammaPod Stereotactic Radiotherapy System for Breast Cancer Treatment
Technology | Stereotactic Body Radiation Therapy (SBRT) | December 22, 2017
The U.S. Food and Drug Administration (FDA) has cleared the new GammaPod noninvasive stereotactic radiotherapy system...
RaySearch Launches RayCare Oncology Information System

Image courtesy of RaySearch Laboratories

Technology | Oncology Information Management Systems (OIMS) | December 22, 2017
RaySearch announced the first release of RayCare, a new oncology information system (OIS) designed to connect the...
RaySearch Releases RayStation 7 Radiotherapy Treatment Planning System
Technology | Treatment Planning | December 19, 2017
RayStation 7, the latest release of RaySearch’s radiation therapy treatment planning system, adds new functionality and...
Overlay Init